mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor MicroenvironmentMichael Haas, Walter Newman|Molecular Cancer Research|2020Cited by 69
<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>anti‐DKK1</scp> therapeutic <scp>DKN</scp> ‐01Edward J. Jarman, Luke Boulter, Marta Horcas‐Lopez et al.|Liver International|2022Cited by 20
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R. Wise, Kwok‐Kin Wong, Arjun Vasant Balar et al.|Prostate Cancer and Prostatic Diseases|2024Cited by 9